Navigation Links
Ritter Pharmaceuticals Hires Dr. Howard Foyt as Executive Vice President, Development & Chief Medical Officer
Date:9/10/2009

LOS ANGELES, Sept. 10 /PRNewswire/ -- Ritter Pharmaceuticals, Inc. (Ritter) has hired Howard Foyt, M.D., Ph.D., FACP as its new Executive VP, Development & Chief Medical Officer. Dr. Foyt brings 13 years of expertise in drug development to Ritter, as the Company prepares to file an IND for its therapy for Lactose Intolerance.

Dr. Foyt will join Ritter's senior management team and oversee the Company's clinical development efforts. Ritter will take advantage of Dr. Foyt's leadership in drug development within big pharma and biotech companies. For the past three years, Dr. Foyt served as VP, Clinical Development and Chief Medical Officer at Metabasis Therapeutics, where he was responsible for five drugs in clinical development over multiple therapeutic areas. Dr. Foyt had previously worked at Pfizer, where he served as Senior Director and Site Head - Diabetes & Obesity, and earlier at Parke-Davis for over ten years participating in the clinical development of multiple drugs mainly in the metabolic disease field. Prior to joining Parke-Davis, Dr. Foyt was on the faculty at the University of Texas Medical Branch, Galveston, TX. He earned his medical degree and Ph.D. in Cell Biology from Baylor College of Medicine. Dr. Foyt completed his residency in internal medicine at Baylor and an endocrinology fellowship at the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.

"We are thrilled to have Dr. Foyt on our team," said Ritter Pharmaceuticals' President and CEO Andrew Ritter. "His breadth of clinical development and drug development experience will bring a great deal of scientific rigor and creativity to our development plans."

About Ritter Pharmaceuticals

Ritter is committed to the discovery, development and commercialization of innovative therapies for gastrointestinal diseases. The Company's scientific platform of gastrointestinal physiology, metabolism and gut adaptation brings creativity to providing unique therapeutic approaches to a variety of GI diseases, including lactose intolerance, irritable bowel syndrome, Crohn's disease, and ulcerative colitis. Ritter's ultimate goal is to improve digestive health and overall quality of life.

Ritter's first compound, RP-G28, has been developed for the treatment of lactose intolerance. RP-G28 will effectively stand out as the first FDA-approved drug for the treatment of lactose intolerance.

www.ritterpharma.com


'/>"/>
SOURCE Ritter Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Reportlinker Adds US and European Radiopharmaceuticals Market Report
2. Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever
3. Isis Pharmaceuticals to Present at Morgan Stanleys Global Healthcare Unplugged Conference
4. Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
5. Jazz Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Amira Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
8. Steven Holtzman Joins Satori Pharmaceuticals Board of Directors
9. Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer
10. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2010
11. Isis Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified ... be personalized through a fitness app. The fitness app plans to fix the two major ... only offer a one size fits all type program , They don’t eliminate ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... Pharma News Issue 52" report to their offering. ... in influenza treatment creates a favourable commercial environment for MedImmune ... growing patient base that will serve to drive considerable growth ... vaccine would serve to cap sales considerably, but development is ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today that ... Supplier Horizon Award . One of ... was recognized for its support of Premier members through ... clinical excellence, and commitment to lower costs. ... this recognition of our outstanding customer service from Premier," ...
Breaking Medicine Technology: